I opened $CVS VERTICAL 240628 CALL 62.0/CALL 61.0$  ,🏥 CVS Health has been under the microscope lately, and the view is increasingly cautious. In the past month, the consensus estimate for this year's earnings has slightly dipped to $7.02, reflecting a subtle yet telling retreat of 0.1%. This downward revision isn't just a number; it’s a hint at analysts' growing skepticism about CVS’s near-term earnings potential. Adding pressure, CVS faces stiff challenges within the healthcare sector, including unfavorable drug pricing and tough reimbursement conditions that are weighing heavily on its performance. Compounding these headwinds is the influx of new competitors, eager to carve out their share of the market, further intensifying the battle for profitability. Furthermore, as we teased apart the dealers' positioning on the options flow, there is strong bias to the downside with much positive VEX for prices below $60. With these factors at play, adopting a short bear call spread sounds like a decent strategic move to bet on CVS’s potential to underperform in the coming months. ⬇️